Beau R. Webber

TL;DR: This study provides proof-of-concept for TALen-mediated in situ correction of an endogenous patient-specific gene mutation and used an unbiased screen for comprehensive TALEN target mapping that will cooperatively facilitate translational application.

TL;DR: It is demonstrated that EditR is a robust, inexpensive tool that will facilitate the broad application of base editing technology, thereby fostering further innovation in this burgeoning field of gene editing.

TL;DR: The megaTAL and CRISPR/Cas9 reagents exhibited the highest disruption efficiency combined with low levels of toxicity and off-target cleavage, and were used for a translatable manufacturing process to produce safe cellular substrates for next-generation immunotherapies.

TL;DR: In this paper, base editor technology was applied for multiplex gene modification in primary human T cells in support of an allogeneic CAR-T platform and demonstrated that base editor can mediate highly efficient multiple-x gene disruption with minimal double-strand break induction.

TL;DR: A highly efficient method for editing the genome of human NK cells using CRISPR/Cas9 to knock out inhibitory signaling molecules and it is demonstrated that these gene-edited NK cells have significantly improved activity, cytokine production, and cancer cell cytotoxicity.